Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616196 · ClinicalTrials.gov registry record · Phase 1
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
A Phase 1 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04616196 is a Phase 1 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT04616196, a Phase 1 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).
Interventions
- DRUG Cetuximab
- DRUG NKTR-255
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-10-30 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04616196
The ClinicalTrials.gov registry entry for NCT04616196 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT04616196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04616196 about?
NCT04616196 is a clinical study titled "Study of NKTR 255 in Combination With Cetuximab in Solid Tumors". This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).
What is the current status of trial NCT04616196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-10-30. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT04616196?
The interventions under investigation include: Cetuximab (DRUG), NKTR-255 (DRUG).
Who is sponsoring clinical trial NCT04616196?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.